Metastatic Melanoma in the Older Patient

Immunologic Insights and Treatment Outcomes

Upendra P Hegde; Nitya Chakraborty; Bijay Mukherji; Jane M Grant Kels


Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(2):185-193. 

In This Article

Five-year View

It is becoming increasingly clear that the elderly white population in general and older males in particular are at the highest risk of developing CM, resulting in increasing mortality from this cancer. Thus, an increasing number of elderly melanoma patients will require effective treatment of CM. Efforts are needed to improve public health education and screening activities targeting this high-risk group of patients to facilitate early diagnosis of CM and improved outcomes. Research activities focusing on changes in the immune system with aging and their relevance to treatment of patients with cancer in general, and melanoma in particular, will continue to expand. These efforts are likely to result in the inclusion of elderly patients in immune-based treatment of cancer. A greater emphasis will need to be put on accrual of elderly melanoma patients in clinical trials to understand the impact of diverse novel treatments in elderly patients with CM.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.